Novo A/S, the holding company for the Novo Group and fully owned subsidiary of the Novo Nordisk Foundation, has announced plans to acquire a 19.95 percent stake in UK medical products and technologies group ConvaTec for around for £1.01 billion.
Headquartered in Reading, ConvaTec – once a division of Bristol-Myers Squibb – has a strong foothold in the areas of advanced wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other chronic conditions.
Under the deal, Novo will also obtain the right to appoint one director to the ConvaTec Board, and is currently proposing to put forward its chief executive Kasim Kutay for this position.
“Novo A/S is an experienced long-term healthcare investor and we see their shareholding in ConvaTec as a validation of the quality and long-term potential of the Company,” said Sir Christopher Gent, chairman of ConvaTec, commenting on the move. “We are also pleased to welcome Kasim to the Board of ConvaTec – we look forward to benefiting from his long experience in the healthcare sector.”
“ConvaTec is a very attractive investment opportunity given the fundamentals of the medical products sector and the strength of the company’s product portfolio,” said Kutay, explaining Novo’s interest in the deal.
By Selina McKee
Source: Pharma Times
Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.
The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.
Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.